Anti-INAR1/ IFNAR1/ AVP monoclonal antibody

Anti-INAR1/ IFNAR1/ AVP antibody for FACS & in-vivo assay

Target products collectionGo to IFNAR1/IFNAR1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T95371-Ab-1/ GM-Tg-hg-T95371-Ab-2Anti-Human IFNAR1 monoclonal antibodyHuman
GM-Tg-rg-T95371-Ab-1/ GM-Tg-rg-T95371-Ab-2Anti-Rat IFNAR1 monoclonal antibodyRat
GM-Tg-mg-T95371-Ab-1/ GM-Tg-mg-T95371-Ab-2Anti-Mouse IFNAR1 monoclonal antibodyMouse
GM-Tg-cynog-T95371-Ab-1/ GM-Tg-cynog-T95371-Ab-2Anti-Cynomolgus/ Rhesus macaque IFNAR1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T95371-Ab-1/ GM-Tg-felg-T95371-Ab-2Anti-Feline IFNAR1 monoclonal antibodyFeline
GM-Tg-cang-T95371-Ab-1/ GM-Tg-cang-T95371-Ab-2Anti-Canine IFNAR1 monoclonal antibodyCanine
GM-Tg-bovg-T95371-Ab-1/ GM-Tg-bovg-T95371-Ab-2Anti-Bovine IFNAR1 monoclonal antibodyBovine
GM-Tg-equg-T95371-Ab-1/ GM-Tg-equg-T95371-Ab-2Anti-Equine IFNAR1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T95371-Ab-1/ GM-Tg-hg-T95371-Ab-2; GM-Tg-rg-T95371-Ab-1/ GM-Tg-rg-T95371-Ab-2;
GM-Tg-mg-T95371-Ab-1/ GM-Tg-mg-T95371-Ab-2; GM-Tg-cynog-T95371-Ab-1/ GM-Tg-cynog-T95371-Ab-2;
GM-Tg-felg-T95371-Ab-1/ GM-Tg-felg-T95371-Ab-2; GM-Tg-cang-T95371-Ab-1/ GM-Tg-cang-T95371-Ab-2;
GM-Tg-bovg-T95371-Ab-1/ GM-Tg-bovg-T95371-Ab-2; GM-Tg-equg-T95371-Ab-1/ GM-Tg-equg-T95371-Ab-2
Products NameAnti-IFNAR1 monoclonal antibody
Formatmab
Target NameIFNAR1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IFNAR1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-873Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
    BiosimilarGMP-Bios-ab-026Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody
    BiosimilarGMP-Bios-INN-871Pre-Made Interferon Alfa Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
    BiosimilarGMP-Bios-INN-725Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
    BiosimilarGMP-Bios-INN-872Pre-Made Interferon Alfacon-1 Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
    Target AntigenProducts DevelopingMulti-species INAR1/ IFNAR1/ AVP VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T95371-Ag-1interferon-alpha/beta receptor alpha chain-like (IFNAR1) protein
    ORF Viral VectorvGMLP002768human IFNAR1 Lentivirus particle
    ORF Viral VectorpGMLP002768human IFNAR1 Lentivirus plasmid


    Target information

    Target IDGM-T95371
    Target NameIFNAR1
    Gene ID3454,15975,288264,699604,609830,101092535,282257,100063402
    Gene Symbol and SynonymsAVP,Ifar,IFN-alpha-REC,IFNAR,IFNAR1,IFNBR,IFRC,IMD106,Infar
    Uniprot AccessionP17181,Q04790
    Uniprot Entry NameINAR1_HUMAN,INAR1_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000142166
    Target ClassificationCheckpoint-Immuno Oncology

    The target: IFNAR1, gene name: IFNAR1, also named as AVP, IFN-alpha-REC, IFNAR, IFNBR, IFRC. The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. The protein belongs to the type II cytokine receptor family and functions as an antiviral factor. [provided by RefSeq, Jul 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.